title: [Organ and function preservation in urethral cancer].
abstract: Primary urethral carcinomas are rare tumors that can occur both in men and women. Histological patterns of these tumors are mixed, urothelial tumors occur as well as squamous cell tumors or adenocarcinomas.There are different clinical factors that define clinical prognosis, and the 1- and 5-year cancer-free survival is 75% and 54%. Therapy of locally limited disease is surgical resection, and organ-preserving treatment is possible if negative frozen sections prove complete surgical resection. However, in men a perineal urethrostomy might be necessary, and in women there is a high risk of urinary incontinence if more than 2 cm of the distal urethra is resected.In case of locally advanced tumors or tumors of the proximal urethra, a radical urethrectomy with supravesical urinrary diversion is necessary. In some cases neoadjuvant (radio-)chemotherapy may be an option.
authors.affiliation: Urologische Klinik und Poliklinik, Klinikum Großhadern, Ludwig-Maximilians-Universität, München, Marchioninistraße 15, 81377, München, Deutschland, Stefan.Tritschler@med.uni-muenchen.de.
authors.forename: S
authors.initials: S
authors.lastname: Tritschler
authors.forename: K
authors.initials: K
authors.lastname: Lellig
authors.forename: A
authors.initials: A
authors.lastname: Roosen
authors.forename: A
authors.initials: A
authors.lastname: Horng
authors.forename: C
authors.initials: C
authors.lastname: Stief
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D019060:Minimally Invasive Surgical Procedures / Q000379:methods*; D059351:Organ Sparing Treatments / Q000379:methods*; D058958:Organs at Risk / Q000601:surgery*; D020127:Recovery of Function; D014523:Urethral Neoplasms / Q000628:therapy*; D013520:Urologic Surgical Procedures / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents
references.citation: Urology. 2006 Dec;68(6):1164-8
references.pmid: 17141838
references.citation: Eur Urol. 2013 Nov;64(5):823-30
references.pmid: 23582479
references.citation: Urol Oncol. 2013 Oct;31(7):1171-7
references.pmid: 22534087
references.citation: Eur J Cancer. 2011 Nov;47(17):2493-511
references.pmid: 22033323
references.citation: J Urol. 2008 Feb;179(2):536-41; discussion 541
references.pmid: 18076921
references.citation: Eur J Cancer. 2012 Mar;48(4):456-64
references.pmid: 22119351
references.citation: Int J Urol. 2004 Aug;11(8):678-82
references.pmid: 15285764
references.citation: Urol Oncol. 2004 Sep-Oct;22(5):404-9
references.pmid: 15464921
references.citation: Urology. 1999 Jun;53(6):1126-32
references.pmid: 10367840
references.citation: Urology. 1998 Sep;52(3):487-93
references.pmid: 9730466
references.citation: J Urol. 1995 Jun;153(6):1918-20
references.pmid: 7752354
references.citation: Onkologie. 2001 Feb;24(1):48-52
references.pmid: 11441281
references.citation: Urol Clin North Am. 2010 Aug;37(3):445-57
references.pmid: 20674699
references.citation: BJU Int. 2007 Jul;100(1):82-7
references.pmid: 17488307
references.citation: World J Urol. 2013 Feb;31(1):147-53
references.pmid: 22614443